CPP Investments

News, insights, analysis and data

← Back to CPP Investments profile

CPP Investments related stories

All articles and analysis

  • Side Letter: Selling LPs on single-assets; PE's talent war; Astorg's €1.3bn
    Private Equity News & AnalysisPEI Staff- 16 February 2022

    GPs are finding novel ways to source capital for single-asset secondaries transactions. Plus: Private equity firms are paying through the nose to compete for top talent and France's Astorg has closed its debut mid-cap fund above target. Here's today's brief, for our valued subscribers only.

  • CPPIB approves $943m in commitments
    Thomas Brown- 14 February 2022

    The Toronto-based public pension has backed seven private equity vehicles.

  • Where next for ESG reporting?
    Amy Carroll- 1 February 2022

    A high-profile agreement on standardised metrics marks an important first step, but LPs will soon be wanting more.

  • Performance watch: Clearlake's PE funds
    Private Equity News & AnalysisCarmela Mendoza- 27 January 2022

    The California-based firm is eyeing up to $13.75bn for its seventh flagship fund, investor documents show.

  • Canalyst secures $70m in Dragoneer-led Series C financing
    News BriefsIris Dorbian- 18 January 2022

    Canalyst, a Vancouver-based financial data and analytics provider, has secured $70 million in Series C financing.

  • Apollo to back microelectronics single-asset deal
    Firms & FundsRod James- 13 January 2022

    The firm entered the private equity secondaries market in April and led its first deal in May, involving an Alpine Investors portfolio company.

  • TPG’s secondaries unit debuts in CCMP GP-led deal
    Firms & FundsChris Witkowsky- 11 January 2022

    The firm's group is among a new crop of secondaries buyers joining a market that continues to grow at a frenetic pace.

  • Emerging markets: Down, but by no means out
    Editor's ViewAlex Lynn and Rod James- 6 January 2022

    A subdued fundraising environment belies soaring investment activity as the pandemic catalyses many of the dynamics that have traditionally drawn private capital to emerging markets.

  • Eikon Therapeutics inks Series B
    News BriefsIris Dorbian- 6 January 2022

    Eikon Therapeutics Inc, a California-based drug discovery and development company, has secured $517.8 million in Series B financing.

  • Side Letter: Secondaries in 2022; Continuation for corporates; Azalea makes bank
    Private Equity News & AnalysisPEI Staff- 5 January 2022

    With secondaries very much on the ascendancy, Private Equity International asked some of the market's best and brightest to predict the year ahead. Plus: KPS founder Michael Psaros explains why corporate carve-outs can resemble continuation vehicles. Here's today's brief, for our valued subscribers only.